Held by 5 specialist biotech funds
High Convergence**Signal Note: Perceptive Advisors Initiates $15M DXCM Position** Edelman's entry into DexCom signals conviction in the CGM market's runway, likely driven by (1) expanding reimbursement for non-diabetic populations (GLP-1 co-users, prediabetes), (2) G7 adoption acceleration post-FDA clearance, and (3) international scale-up, particularly in Europe.
AI analyst context — unlock full analysis
**Signal Note: Deerfield Initiates DexCom Position** Deerfield's $2.2M entry into DXCM suggests confidence in continuous glucose monitoring (CGM) market expansion, likely driven by recent label expansions (Type 2 diabetes non-insulin users cleared by FDA in 2022) and growing reimbursement tailwinds. The position sizing indicates a tactical allocation rather than conviction play, consistent with Deerfield's multi-strategy approach to healthcare infrastructure plays with near-term visibility.
+ 3 more positions with dollar amounts and AI context
Unlock All — 7-Day Free Trial